12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Simeprevir: Phase III data

The open-label, Japanese Phase III CONCERTO-2 trial in 106 patients with chronic HCV genotype 1 infection who failed to respond to previous interferon-based therapy showed that once-daily 100 mg oral simeprevir for 12 weeks plus peginterferon alfa-2a and ribavirin for 24 or 48 weeks led to an SVR12 rate of 52.8% and an SVR24 rate of 50.9%. In patients who received once-daily 100 mg oral simeprevir for 24 weeks plus peginterferon alfa-2a and ribavirin for...

Read the full 355 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >